Get the Stockscreener App
5.99
7.56%
-0.49
After Hours:
6.00
0.010
+0.17%
Cogent Biosciences Inc stock is traded at $5.99, with a volume of 2.18M.
It is down -7.56% in the last 24 hours and down -20.45% over the past month.
See More
Previous Close:
$6.48
Open:
$6.24
24h Volume:
2.18M
Relative Volume:
1.66
Market Cap:
$752.55M
Revenue:
-
Net Income/Loss:
$-242.30M
P/E Ratio:
-2.4153
EPS:
-2.48
Net Cash Flow:
$-192.10M
1W Performance:
-19.05%
1M Performance:
-20.45%
6M Performance:
-44.54%
1Y Performance:
-10.86%
1-Day Range:
$5.89
$6.44
1-Week Range:
$5.89
$7.49
52-Week Range:
$5.88
$12.61
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
5.99 | 752.55M | 0 | -242.30M | -192.10M | -2.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
When Would Be The Best Time To Buy Cogent Biosciences Inc (NASDAQ: COGT) Stock? - stocksregister.com
21,653 Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) Bought by Quantbot Technologies LP - Defense World
Swiss National Bank Sells 3,000 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate - Yahoo Finance
Proficio Capital Partners LLC Buys New Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences Announces Multiple Poster Presentations - GlobeNewswire
Cogent Biosciences Announces Multiple Poster Presentations At 2025 American Association For Cancer Research (AACR) Annual Meeting - MarketScreener
Cogent's Cancer Breakthrough: 4 Precision Therapies Target KRAS, HER2, and Drug Resistance - StockTitan
Charles Schwab Investment Management Inc. Boosts Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Bank of New York Mellon Corp Has $2.02 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Is Cogent Biosciences (COGT) Stock A Solid Choice Right Now? - Barchart
Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? - Nasdaq
Cogent Biosciences (COGT): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Is Cogent Biosciences, Inc. (COGT) a Best Biotech Stock According to Billionaires? - Yahoo Finance UK
Proficio Capital Partners LLC Invests $93,000 in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Gastrointestinal Stromal Tumor Treatment Market Size Report - openPR
Cogent Biosciences (NASDAQ:COGT) Earns Sector Outperform Rating from Analysts at Scotiabank - Armenian Reporter
Scotiabank Begins Coverage on Cogent Biosciences (NASDAQ:COGT) - Defense World
Scotiabank Initiates Coverage of Cogent Biosciences (COGT) with Sector Outperform Recommendation - Nasdaq
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.00 Average Target Price from Brokerages - Defense World
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference - The Manila Times
Cogent Biosciences initiated with an Outperform at Scotiabank - TipRanks
New York State Common Retirement Fund Has $180,000 Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
When the Price of (COGT) Talks, People Listen - Stock Traders Daily
Buy Rating for Cogent Biosciences Backed by Promising Clinical Trial Results and Market Potential - TipRanks
Q1 EPS Forecast for Cogent Biosciences Increased by Analyst - Defense World
Needham & Company LLC Reiterates Hold Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Cogent Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks
Cogent Biosciences: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks
Cogent Biosciences Announces SUMMIT Continues to Showcase - GlobeNewswire
Cogent Biosciences Reports 65% Improvement In Symptom Score From Bezuclastinib In NonAdvSM - Nasdaq
Cogent Biosciences announces expanded results from OLE portion of SUMMIT trial - TipRanks
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Yahoo Canada Finance
Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Cogent Biosciences: Promising Pipeline and Market Opportunities Justify Buy Rating - TipRanks
Cogent Biosciences (COGT) Surprises Wall Street with Narrower-Than-Expected Q4 Loss - HPBL
Cogent Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cogent Biosciences (COGT) Reports Q4 2024 Net Loss of $67.9 Mill - GuruFocus
Cogent Biosciences, Inc. SEC 10-K Report - TradingView
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Can Cogent's Triple Catalyst Year Transform Rare Disease Treatment? 3 Key Trial Results Coming in 2025 - StockTitan
Cogent Biosciences (COGT) Projected to Post Earnings on Monday - Defense World
Long Term Trading Analysis for (COGT) - Stock Traders Daily
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9%Time to Sell? - MarketBeat
Leerink Partnrs Has Strong Forecast for COGT FY2025 Earnings - MarketBeat
You might want to take a look at Cogent Biosciences Inc (COGT) now - SETE News
Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Target Price at $14.33 - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9% – What’s Next? - Defense World
Investing in Cogent Biosciences Inc (COGT) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year? - Nasdaq
Cogent Biosciences (NASDAQ:COGT) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):